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Abstract
Background: Metastasis, the spread and growth of tumor cells to distant organ sites, represents the most devastating
attribute and plays a major role in the morbidity and mortality of cancer. Inflammation is crucial for malignant tumor
transformation and survival. Thus, blocking inflammation is expected to serve as an effective cancer treatment. Among anti-
inflammation therapies, chemokine modulation is now beginning to emerge from the pipeline. CXC chemokine receptor-4
(CXCR4) and its ligand stromal cell-derived factor-1 (CXCL12) interaction and the resulting cell signaling cascade have
emerged as highly relevant targets since they play pleiotropic roles in metastatic progression. The unique function of CXCR4
is to promote the homing of tumor cells to their microenvironment at the distant organ sites.
Methodology/Principal Findings: We describe the actions of N,N9-(1,4-phenylenebis(methylene))dipyrimidin-2-amine
(designated MSX-122), a novel small molecule and partial CXCR4 antagonist with properties quite unlike that of any other
reported CXCR4 antagonists, which was prepared in a single chemical step using a reductive amination reaction. Its
specificity toward CXCR4 was tested in a binding affinity assay and a ligand competition assay using
18F-labeled MSX-122.
The potency of the compound was determined in two functional assays, Matrigel invasion assay and cAMP modulation. The
therapeutic potential of MSX-122 was evaluated in three different murine models for inflammation including an
experimental colitis, carrageenan induced paw edema, and bleomycin induced lung fibrosis and three different animal
models for metastasis including breast cancer micrometastasis in lung, head and neck cancer metastasis in lung, and uveal
melanoma micrometastasis in liver in which CXCR4 was reported to play crucial roles.
Conclusions/Significance: We developed a novel small molecule, MSX-122, that is a partial CXCR4 antagonist without
mobilizing stem cells, which can be safer for long-term blockade of metastasis than other reported CXCR4 antagonists.
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Introduction
Chemokines are small, pro-inflammatory cytokines of approx-
imately 10 kDa that orchestrate a diverse set of activities through
interaction with their cognate receptors. Coupling of stromal cell
derived factor 1 (SDF-1; CXCL12) with its receptor CXCR4,
which was previously identified as a major coreceptor for the
entry of T-tropic HIV [1,2,3,4], plays critical roles in inflamma-
tion [5], as well as cancer metastasis [6]. The invasion of cancer
cells into surrounding tissue is associated with considerable
destruction and regeneration of intercellular elements [7]. Newly
synthesized stroma, known as ‘‘cancer-induced stroma,’’ is
composed of inflammatory cells (including lymphocytes, granu-
locytes, and macrophages), endothelial cells of blood and lymph
vessels, pericytes, and fibroblasts. Solid tumors are often
infiltrated with leukocytes and macrophages. In some tumors,
leukocytes can account for up to 50% of the tumor mass, the
most represented subsets being lymphocytes and tumor-associat-
ed macrophages (TAMs). The presence of TAM at the tumor site
represents one of the hallmarks of cancer associated inflammation
[8]. TAMs derive from circulating monocytes that are selectively
attracted within the tumor microenvironment by locally pro-
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cytes differentiate in the tumor microenvironment to tissue
resident macrophages. In turn, several TAM products have been
shown to directly stimulate the growth of tumor cells. Addition-
ally, TAMs also contribute to the angiogenic switch by releasing
angiogenic factors (VEGF, FGF, and CXCL12) and to the
degradation and remodeling of the matrix with metalloproteases
(MMPs), suggesting an important role in neovascular formation
and subsequent tumor progression [9]. In addition, the CXCR4/
CXCL12-axis has been shown to play a pivotal role in trafficking
and homing of normal stem cells and metastasis of cancer stem
cells to organs that express high levels of CXCL12, such as the
lymph nodes, lungs, liver, and bone [10,11]. Homing, the
mechanism that allows foreign tissue-origin cells to reside and
proliferate, is believed to be the rate-limiting step of the multi-step
metastatic process [12]. Kang et al. generated an animal model of
bone metastasis by the intercardiac injection of MDA-MB-231
breast cancer cells into female SCID mice [13]. A subsequent
microarray analysis on a sub-population of MDA-MB-231 cells
with elevated metastatic activity isolated from the mouse showed
that one of the six genes responsible for the metastatic phenotype
was CXCR4, which was responsible for homing of breast tissue-
origin tumor cells to bone. In samples collected from various
breast cancer patients, Muller et al [14] found that the level of
expression of CXCR4 is higher in primary tumors relative to
normal mammary glands or mammary epithelial cells. By
contrast, CXCL12 is highly expressed in the most common
destinations of breast cancer metastasis including the lymph
nodes, lung, liver, and bone marrow. Taken together, CXCR4
and CXCL12 may indeed play critical roles in breast cancer
metastasis. Thus, it is important to develop anti-CXCR4
compounds that can intervene in this interaction. The expression
of CXCR4 has been detected in 23 different types of cancers,
making it the most common chemokine receptor expressed on
cancer cells [15]. There is a significant volume of literature
demonstrating that CXCR4 and CXCL12 play critical roles in
cancer metastasis in numerous types of cancers [16] and it is
important to develop anti-CXCR4 compounds to intervene in
this progression.
The current clinical lead compound, AMD3100, is a metal-
chelating bicyclam that has been shown to block calcium flux
induced by CXCR4 activation. Its chelating properties are likely
related to the cardiotoxicity reported in its clinical trial against
HIV [17]. AMD3100 was recently approved by the FDA for stem
cell mobilization. While AMD3100 can benefit patients with
certain diseases, it can also induce lung or liver fibrosis [18], and
the mobilized cells may act as potential cancer stem cells [19].
Therefore, while limited single use of AMD3100 is widely
accepted, drugs with improved toxicity profiles will be required
for long term clinical use. We had previously reported that
blocking the CXCR4/CXCL12 interaction with a peptidic
CXCR4 antagonist, TN14003, suppresses lung metastasis in
models of breast cancer [20] and head and neck cancer [21]. In
addition, we reported that TN14003 blocks bleomycin-induced
lung fibrosis [22]. Although the TN14003 results provided an
important proof of concept, its lack of oral availability promted us
to look for alternatives that possessed better phamacologic profiles.
Using TN14003 as our benchmark, we herein report the
development of a novel, small molecule CXCR4 modulator,
MSX-122, that specifically blocks selected functions of CXCR4.
Since a large patient population can benefit from anti-metastasis
treatment, our drug could potentially have a significant impact on
human health.
Results
Chemistry
Initially, we proposed that inclusion of a nitrogen atom in each
of the terminal aromatic rings (i.e., pyridyl instead of phenyl) might
impede rapid oxidative metabolism and improve inhibitor
pharmacokinetic profiles. This working hypothesis was validated
in our previously reported structure-activity relationship (SAR)
study that led to discovery of WZ811 [23]. A second nitrogen atom
substitution in the terminal aromatic rings (i.e., pyrimidyl), which
was designated as MSX-122, further improved the pharmacoki-
netic profile. This compound was prepared in a single chemical
step using a reductive amination reaction (Figure 1A) [24].
Screening for Anti-CXCR4 Small Molecules via Selected in
vitro Assays
For primary compound screening, the previously reported
binding affinity assay was utilized [23] (Figure 1B). Although
CXCL12 can also interact with the CXCR7 chemokine receptor
[25,26], our screening was specific for CXCR4, since the MDA-
MB-231 cells used for primary screening express insignificant
levels of CXCR7 (Figure 1C). Effective concentration for MSX-
122 was at a low nanomolar (the concentration at which each
compound blocks more than 50% of TN14003 binding on
CXCR4).
MSX-122 cannot block
125I-labeled full length CXCL12
binding to CXCR4 (data not shown), while the reports about
AMD3100 are controversial [27,28,29,30]. This may be due to the
fact that CXCL12, a 10 kDa peptide, has multiple interaction sites
on CXCR4 [27,31]. However, we anticipated that CXCL12
would block MSX-122 binding to CXCR4 because MSX-122
binds to a CXCL12 binding site on CXCR4. To determine
whether MSX-122 directly binds to the CXCL12 site on CXCR4,
we utilized highly sensitive radiotracer technique, using a fluorine-
18 radiolabeled MSX-122 analog (MSX-122F) in which one
pyrimidine ring of MSX-122 was labeled by fluorine-18
(Figure 1D). Then, we tested whether preincubation with
CXCL12 before adding [
18F]MSX-122F blocked binding to
CXCR4 in the CXCR4-positive metastatic squamous cell
carcinoma of head and neck (SCCHN) cells that we established
from a poorly metastatic parental cell line by four rounds of in vivo
selection using a lymph node metastatic xenograft mouse model.
These metastatic SCCHN cell lines expressed high levels of
CXCR4 while non-metastatic parental cells did not [21,32]. As
anticipated, inhibition occurred in a dose-dependent manner
(Figure 1D). Although the MSX-122F is a fluorinated compound,
it behaves the same as MSX-122 in all the in vitro screening assays
employed.
CXCR4/MSX-122 Docking Model
The published crystallographic structure of CXCR4, bound by
the small molecule antagonist IT1t (2.5 A ˚ resolution; PDB code:
3ODU) [33] (Data S2), has been utilized to explore the interaction
of MSX-122 with CXCR4 and in comparison to IT1t, a CXCR4
antagonist. Thus, IT1t was removed from the complex, and the
flexible ligand Glide docking methodology with extra precision
[34,35,36] was employed to predict binding poses for MSX-122 in
the binding site of 3ODU/CXCR4. The resulting binding poses
were subsequently sorted by energy with the MM-GBSA scoring
algorithm, which provides an estimate of relative binding free
energies [37,38]. A predicted binding pose of low energy is shown
in Figure 1E. MSX-122 (magenta) resides in close proximity to
the binding locale occupied by a TN14003 analog in the rather
spacious pocket. The docking result is consistent with Gupta’s
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signal transduction without displacement of CXCL12 because
CXCL12 interacts via multiple sites, one being the N-terminal
segment of CXCR4 at the receptor surface [27,31]. Thus, it is not
unreasonable to postulate that a large molecule such as TN14003
can displace CXCL12 binding to CXCR4, while MSX-122 near
the bottom of the binding pocket cannot. Nonetheless, we
postulate that MSX-122 bound to CXCR4 can interfere with
the ‘‘lock and key’’ mechanism between CXCR4 and CXCL12,
which can result in inhibiting key functional signaling such as
Matrigel invasion and cAMP modulation without displacing
CXCL12.
Secondary Function Assays
For secondary screening assays, we utilized three functional
assays that use the full-length CXCL12 ligand. We previously
reported that TN14003 effectively blocks CXCL12-mediated
invasion of MDA-MB-231 cells in a Matrigel invasion assay using
CXCL12 as a chemoattractant [20]. As shown in Figure 2A,
100 nM MSX-122 effectively blocked invasion of 78% MDA-MB-
231 cells while the same concentration of AMD3100 blocked
invasion of 62% cells. CXCR4 and CXCL12 are also known to
play critical roles in endothelial cell migration and tubular
organization. While AMD3100 at 100 nM blocked 43% of
CXCL12-induced tubular network formation, MSX-122 blocked
63% at the same concentration (Figure 2B).
Lastly, we utilized a cAMP assay as a secondary functional assay
[23]. As a GPCR, CXCR4 binds CXCL12 and activates G-
protein mediated signaling through the Gai pathway that reduces
cAMP levels within cells. While MSX-122 counteracted CXCL12
function effectively at concentrations as low as 10 nM, 1000 nM
AMD3100 was required to significantly block CXCL12 function
(Figure 3A). We also determined whether CXCL12 alters cAMP
levels in CXCR4-negative (wild-type) vs. CXCR4-transfected
MDA-MB-435 cells to ensure that the cAMP changes in this assay
are CXCR4-specific. It is noteworthy that neither MDA-MB-435
cells nor CXCR4-transfected MDA-MB-435 cells express CXCR7
(Figure 3B). As anticipated, cAMP levels were not influenced by
CXCL12 in CXCR4-negative, wild-type MDA-MB-435 cells
(Figure 3C), in contrast to CXCR4-transfected MDA-MB-435
cells (Figure 3D). MSX-122 was also tested against other
chemokine receptors (e.g., CCR3 and CCR5) for cross-reactivity,
but it did not block cAMP reduction mediated by their
corresponding ligands CCR3/CCL5 and CCR5/CCL5 (data
not shown).
Two other in vitro assays demonstrated that MSX-122 exhibits a
different profile than AMD3100 and other reported anti-CXCR4
compounds: (1) MSX-122 did not inhibit T-tropic HIV infection
(via the formation of the CXCR4/CD4/GP120 complex), while
AMD3100 did [17]; and (2) unlike AMD3100, MSX-122 proved
to be inactive in our calcium flux assay.
Anti-inflammatory Efficacy of MSX-122 in Three Different
Animal Models
Murine experimental colitis model. We sought to
determine the therapeutic potential of MSX-122 by determining
its profile in several in vivo assays associated with anti-CXCR4
properties. Previously, a TN14003 peptide analog and AMD3100
have been shown to block murine experimental colitis [39,40]. To
determine the efficacy of MSX-122 in this model, mice were
Figure 1. Synthesis of MSX-122 and in vitro functional assays. (A) Scheme of MSX-122 preparation. (B) Representative immunofluorescence
images show competition-binding assay using the biotinylated CXCR4 antagonist TN14003. MDA-MB-231 cells on an 8-well slide chamber were
treated with TN14003 or MSX-122 at various concentrations for 15 minutes at room temperature. The cells were subsequently fixed and incubated
with biotin-labeled TN14003 (0.05 mg/ml). After washing, cells were incubated with streptavidin-rhodamine. Red color represents CXCR4. Nuclei were
counterstained with cytox blue. (C) RT-PCR results of CXCR4 and CXCR7 reveal that MDA-MB-231 cells do not express CXCR7. (D) Scheme of fluorine-
18 labeling of MSX-122 is shown. To determine binding of MSX-122 to a CXCL12 binding site on CXCR4, we tested whether preincubation with
CXCL12 (11, 33, 100, and 400 nM) before adding [
18F]MSX-122F blocked binding to CXCR4 in the CXCR4-positive metastatic SCCHN cells. (E) A low
energy predicted binding pose for MSX-122 (magenta) in the CXCR4 X-ray structure (grey) is illustrated by two different visualizations: ribbon (left)
and protein surface (right) representations. The complex was constructed by extracting the small molecule antagonist IT1t from the X-ray structure
(pdb code 3ODU; [33]) followed by docking MSX-122 into the corresponding binding site.
doi:10.1371/journal.pone.0034038.g001
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3 day recovery with or without MSX-122. DSS treatment resulted
in inflammation manifested by extensive mucosal damage,
epithelial erosion, crypt destruction, and infiltration of
inflammatory cells in the mucosa and the lamina propria
(Figure 4A). DSS/MSX-122-treated mice also developed signs
of inflammation, but the degree of epithelial erosion and crypt
destruction was significantly less, consistent with the clinical
assessment, which quantifies the appearance of occult blood and
diarrhea (data not shown). At day 10, colonic damage with crypt
destruction and increased inflammatory cell infiltration remained
in DSS-treated mice. By contrast, the colons of DSS/MSX-122-
treated mice showed signs of recovery. Figure 4B quantitiates
these histological features.
Consistent with the histological differences, a marked decrease
in neutrophil infiltration into the injured tissue (as assessed by
myeloperoxidase (MPO) activity [41]) was observed in DSS/
MSX-122 treated mice when compared with DSS treated mice
(Figure 4C). To elucidate whether MSX-122 action inhibits T-
lymphocyte infiltration in colonic mucosa, we determined the
number of CD4
+ T-cells by immunohistochemical analysis [42]
and found it to be markedly decreased in DSS/MSX-122-treated
mice relative to DSS-treated mice (Figure 4D). These data clearly
demonstrate that inflammation was far less severe in MSX-122-
treated vs. DSS-treated mice.
Since inflammatory cells, including lymphocytes, neutrophils,
and macrophages, express CXCR4, we wanted to determine
whether MSX-122 blocks accumulation of such cells in the
mucosa. DSS-treatment for 7 days significantly increased the
number of CXCR4-positive cells at the sites of ulceration, which
remained elevated at day 10. By comparison, the number of
CXCR4-positive cells was markedly decreased in DSS/MSX122
treated animals relative to the DSS-treated group (Figures 4E,
F). These data show that MSX-122 blocks infiltration of CXCR4-
positive cells in the mucosa.
Since cytokines play a central role as mediators of inflammation,
we next sought to determine the role of CXCR4 in the production
of pro-inflammatory cytokines in the colon of mice by real-time
RT-PCR. In DSS-treated mice, drastic increases in the mRNA
levels of several pro-inflammatory cytokines were observed. MSX-
122 attenuated the production of TNF-a, IL-1b, and IL-6 at
day 7, and further decreased cytokine concentration at day 10
(Figure 4G). INF-c mRNA expression was slightly reduced by
MSX-122 treatment, but did not reach a statistical difference
compared with DSS-treated mice (data not shown). As a
consequence, we conclude that the inhibtion of CXCR4 alters
the cytokine profiles within the mucosa of DSS-treated mice.
There is substantial evidence that inflammatory bowel disease
(IBD), especially Crohn’s disease (CD), is associated with invasive
E.coli, which regulates cytokine expression and epithelial barrier
function within the host environment [43]. To demonstrate that
MSX-122 attenuates the level of TNF-a, a critical inflammatory
cytokine, we assessed TNF-a secretion by J774A.1 macrophages
infected with invasive E coli isolated from inflamed mucosa of
patients with CD, LF82, and 13I, or non-pathogenic EFC-1 as a
control [43,44]. Macrophages were incubated with bacterial
culture in the absence or presence of MSX-122. The CD isolates,
LF82 and 13I, greatly induced TNF-a secretion by macrophages
[43]. The addition of MSX-122 to the culture media during the
bacterial infection significantly attenuated the amount of TNF-a
induced by these strains (Figure 4H), suggesting that CXCR4
plays crucial roles in the host response to the CD-isolated invasive
E.coli.
Figure 2. MSX-122 blocks invasion and angiogenesis in vitro. (A) Micrographs of Matrigel invasion assay induced by CXCR4/CXCL12-mediated
interaction using MDA-MB-231 cells in the presence of anti-CXCR4 compounds. (B) Representative micrographs of the endothelial tubular network
formation in the presence of anti-CXCR4 compounds. HUVECs formed excellent tubular networks in the presence of CXCL12 (#1), but poor tubular
networks when CXCL12 was blocked by prior treatment with 100 nM of AMD3100 (#2) or MSX-122 (#3). The results are summarized in a graph in
the right panel.
doi:10.1371/journal.pone.0034038.g002
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reported utilizing a carrageenan-induced mouse paw edema model
as one of our screening cascades for anti-CXCR4 compounds [45].
It is a widely used test to assess anti-inflammatory activity in vivo,
which is known to involve CXCR4 as a key role in the recruitment
of inflammatory cells to sites of inflammation. An apparent edema
response was seen 24 h after the l-carrageenan injection (compared
to the contralateral paw that was injected with saline). Figure 5A
shows that MSX-122 exhibits more than 50% inhibitory effect on
inflammation. These data confirm that MSX-122 can inhibit
inflammation as anticipated.
Bleomycin-induced lung fibrosis model. Previously, we
had studied the role of the CXCL12/CXCR4-axis in a rodent
model of bleomycin-induced lung injury and reported that
TN14003 blocked bleomycin-induced lung fibrosis [22]. Using
the same model, we tested whether MSX-122 blocks bleomycin-
induced lung fibrosis. Lungs harvested 20 days after bleomycin
treatment were analyzed histologically. None of the MSX-122ms
(salt form was used for better solubility)-treated mice exhibited
lung fibrosis, while bleomycin caused marked increases in collagen
deposition in the control mice (Figure 5B). Thus, treatment with
MSX-122ms completely prevented bleomycin-induced lung
fibrosis, demonstrating superiority over TN14003 [22].
Anti-metastatic Efficacy of MSX-122 in Three Different
Animal Models
To evaluate the anti-metastatic efficacy of MSX-122, we
utilized three different animal models. For breast cancer
metastasis, MDA-MB-231 cells were injected intravenously to
generate an experimental metastasis model. All untreated control
mice developed lung metastases (Figure 6A top), while the group
treated with MSX-122ms, i.p. exhibited significantly fewer lung
metastases (Figure 6A bottom). The estimated average areas of
micrometastases on the lung surface from the control and treated
groups were 47.5% and 13%, respectively (Figure 6B left)a s
confirmed by real-time RT-PCR using primers to detect human
CXCR4 (Figure 6B right).
The anti-metastatic efficacy of MSX-122ms was confirmed in a
model for SCCHN metastasis known for the critical role of
CXCR4 in metastatic progression using [
18F]FDG-PET which is a
standard imaging tool to detect lung metastasis in clinic [21]. In
Figure 7A (left panel), [
18F]FDG-PET axial images of three
randomly selected mice from each group (6 mice in one scan) are
shown (the metastasized SCCHN tumor cells are indicated by
white arrows). When injected with control vehicle, the mice
exhibited significant lung metastases (bottom three mice). By
contrast, the arm administered with MSX-122ms showed no
evidence of metastases, similar to TN14003 [21]. The two panels
on the right (Figure 7A) are the coronal images of the same mice
on the left. The top three mice were treated with MSX-122ms,
while the bottom three mice represent the control.
To further test whether MSX-122 can also inhibit metastatic
progression in an orthotopic mouse model of uveal melanoma
micrometastasis [46,47], melanoma OMM2.3 cells overexpressing
HGF/TGF-b/CXCR4/MMP2 were inoculated into the posterior
chamber of the right eye. After 3 days, MSX-122 treatment was
Figure 3. Comparison of inhibition of cAMP modulation by MSX-122 and AMD3100. (A) With 15 min pre-treatment with MSX-122 or
AMD3100 at various concentrations, the effect of 150 ng/ml of CXCL12 on cAMP reduction was measured by the TR-FRET based LANCE assay kit
using U87CD4CXCR4 cells. (B) RT-PCR analysis of CXCR4 and CXCR7 mRNA in wild-type MDA-MB-435 cells. CXCR4-overexpressing MDA-MB-435 cells
were generated by transfection using a CXCR4 expressing plasmid (Missouri S&T cDNA resource center) and Lipofectamine2000. (C) No effect of MSX-
122 on cAMP reduction induced by 150 ng/ml of CXCL12 in CXCR4-negative, wild-type MDA-MB-435 cells. (D) The effect of MSX-122 on cAMP
reduction induced by 150 ng/ml of CXCL12 in CXCR4-overexpressing MDA-MB-435 cells.
doi:10.1371/journal.pone.0034038.g003
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PLoS ONE | www.plosone.org 5 April 2012 | Volume 7 | Issue 4 | e34038Figure 4. MSX-122 attenuates colonic damage in mice with experimental colitis. (A) Colonic sections were stained with H&E. (B)
Histological scores were determined by a blinded examination of the sections. n=16 per group. *, p,0.05 between DSS and DSS + MSX-122 treated
mice. (C) MPO activity was measured in the colons of control, DSS-, and DSS/MSX-122-treated mice. MPO activity was expressed as unit of MPO per
mg colonic lysate. n=12. *, p,0.05. (D) The presence of CD4
+ lymphocytes was detemined by immunohistochemically using anti-CD4 antibodies.
CD4
+ lymphocytes are depicted in the brown color and nuclei were counter-stained in the blue color. Quantification of CD4
+ lymphocyte per high
powered field is shown. n=4–5. *, p,0.01. (E) Representatives of immnohistological staining of CXCR4-positive cells are shown. CXCR4 protein is
depicted by the brown color, whereas nuclei were counter-stained in blue. 1, control; 2, 7 days DSS; 3, 7 days DSS + 3 days or recovery; 4, 7 days DSS/
MSX-122; and 5, 7 days DSS/MSX-122 + 3 days MSX-122. (F) Quantitative analysis of CXCR4-positive immune cells in the colon is shown. *, p,0.01.
MSX-122 blocks migration of CXCR4 positive cells. (G) Expression of cytokine mRNAs was determined by qRT-PCR. Expression levels of cytokines were
normalized to 18S. n=8. *, p,0.05. (H) MSX-122 attenuates TNF-a secretion induced by invasive E.coli. J774A.1 macrophages in triplicates were
infected with overnight cultures of commensal E.coli EFC-1, CD-isolated E.coli LF82 or 13I at MOI 10:1 for 3 h. Following 3 h infection, macrophage
culture was washed and incubated for additional 21 h in a growth medium containing antibiotics and MSX-122. The amounts of TNF-a in the
supernatant were quantified by ELISA. Representative data from three independent experiments, each performed in triplicate, are shown. *, p,0.05.
doi:10.1371/journal.pone.0034038.g004
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PLoS ONE | www.plosone.org 6 April 2012 | Volume 7 | Issue 4 | e34038Figure 5. MSX-122 inhibits inflammation induced by carrageenan and lung fibrosis induced by bleomycin. (A) Suppression effect of
anti-CXCR4 compounds on carrageenan-induced mouse paw edema. Acute paw inflammation was induced by subcutaneous injection of 50 mLo fl-
carrageenan in one hind paw. The mice in the treatment group were all administered CXCR4 antagonists at 10 mg/kg i.p., while control animals
received corresponding i.p. injections of vehicle. Left panels show the control mice with left paw induced inflammation by carrageenan; right panels
show the treated mice with left paw induced inflammation by carrageenan with about 55% suppression. (B) MSX-122 inhibits bleomycin-induced
pulmonary fibrosis. A total of 20 mice, 10 in each group, received 10 mg/kg, i.p. of MSX-122ms or saline one day before bleomycin treatment and
daily for 20 days. Representative H&E stainings of saline treated control (left) or MSX-122ms treated (right) lung tissues on day 20 after bleomycin
treatment.
doi:10.1371/journal.pone.0034038.g005
Figure 6. MSX-122 blocks metastasis in an experimental animal model of breast cancer metastasis. (A) Representative photographs of 5
lungs were shown from each group. (B) Histological quantization shows a decrease in tumor area in the treated group. Quantitative real-time RT-PCR
of human CXCR4 confirms that animals injected with MDA-MB-231 cells and treated with vehicle develop lung metastasis. On the other hand, animals
injected with MDA-MB-231 cells and treated with MSX-122 (4 mg/kg, i.p., daily) develop significantly less metastasis.
doi:10.1371/journal.pone.0034038.g006
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was enucleated. After 4 weeks, the mice were sacrificed and
hepatic tissues were collected and processed for H&E staining
(Figure 7B). Six sections through the center of the liver were
microscopically examined for the presence of micrometastases,
and the total number of micrometastases in the treatment group
was determined to be 24 (Figure 7B, bar graph). This was
significantly less than the control group at 93 (p,0.05) and
TN14003 at 40 [45].
Discussion
Metastasis is an end result for many solid tumor types and is the
leading cause of cancer related deaths. This process involves
intimate cooperation between tumor cells and their tumor
microenvironment for homing and recruitment of tumor cells as
well as tumor stroma components. Ironically, as of now, there are
no marketed therapies that specifically target and address the
metastatic process. As such, it has attracted an increasing amount
of attention from research groups over the last decade in both
academia and industry, as a target for disease intervention and life
extension. The CXCR4/CXCL12 interaction, and the resulting
cell signaling cascade, has recently emerged as one of the most
relevant such targets as it has been shown to play a key role in
metastatic progression. We have been simultaneously designing
and generating new analogs to optimize their efficacy as well as
expand our structural scope [23,45]. MSX-122 is currently our
most advanced lead, which potently binds to CXCR4, thus,
blocking certain functions of CXCR4/CXCL12 signaling. We
have followed this discovery by demonstrating that MSX-122
inhibits tumor metastasis and inflammation in numerous in vitro
and in vivo studies. Specific screening assays that have been
established for the selection process include in vitro binding
potency, ligand competition, Matrigel invasion, and cAMP
modulation, and CXCR4/MSX-122 docking modeling. We have
also established and validated a number of in vivo models of cancer
metastasis and inflammation that have been utilized here to
establish a proof of efficacy for our lead molecule. The intended
outcome of current work was the development of a unique small
molecule that will effectively attenuate cancer metastasis in vivo by
blocking CXCR4 function whilst demonstrating a specificity
profile to merit advancement into human clinical evaluation.
The anti-inflammatory efficacy of MSX-122 has been tested in
three animal models in which inhibition of CXCR4 is reported to
ameliorate the severity of disease progression. We observed that
DSS/MSX-122-treated mice had shown only moderate signs of
inflammation compared to DSS-treated mice. In addition, we
demonstrated that MSX-122 blocks bleomycin-induced lung
fibrosis involving chemotaxis and homing of CXCR4-positive
mesenchymal progenitor cells into the lungs, the same critical
mechanisms involved in cancer metastasis. Furthermore, MSX-
122 exhibits anti-inflammatory activity in a carrageenan-induced
paw edema model. Consistent with the effect of other known
CXCR4 antagonists, MSX-122 blocks lung metastasis of breast
cancer and SCCHN, and liver metastasis of uveal melanoma in
vivo. These data further support the role of CXCR4 in chemotaxis,
motility, and invasion and reinforce its value as a target for
Figure 7. MSX-122 blocks metastasis in two more animal models for metastasis. (A) Non-invasive [
18F]FDG-PET imaging of lung metastasis
in head and neck cancer animal models. Three randomly selected mice revealed lung metastases in all mice in the control group; significantly less
metastasis was found in the MSX-122 (10 mg/kg i.p., daily) treated group. Left panels show the axial images of three subjects from the control group
(bottom) and three from the treated group (top). Right panels show the corresponding coronal images of the same mice. White arrows indicate
metastasized SCCHN tumor cells. (B) The inhibition effect of MSX-122 (10 mg/kg i.p., daily) in a uveal melanoma micrometastasis animal model.
Micrometastatic clones in liver are shown by small white arrows in the images. MSX-122 significantly decreased the numbers of hepatic
micrometastases.
doi:10.1371/journal.pone.0034038.g007
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play key roles, such as inflammation and cancer metastasis.
A most intriguing aspect of MSX-122 is that it behaves
differently from other reported anti-CXCR4 compounds, espe-
cially AMD3100. MSX-122 is not effective in blocking T-tropic
HIV infections as determined by studies carried out at Monogram
Biosciences (data not shown). MSX-122 is also incapable of
blocking the binding of
125I-labeled CXCL12 to CXCR4.
Consistent with previous reports of multiple interaction sites
between CXCR4 and CXCL12 [27], MSX-122 (molecular weight
,300 daltons) appears to be insufficiently large to block all
binding sites between CXCR4 and CXCL12. However, we
anticipated that CXCL12 would block MSX-122 binding to
CXCR4 because MSX-122 binds to a CXCL12 binding site on
CXCR4. To test this hypothesis, we labeled MSX-122 with
fluorine-18 and tested whether preincubation with CXCL12
before adding [
18F]MSX-122F blocked binding to CXCR4 in the
CXCR4-positive metastatic SCCHN cells. As predicted, CXCL12
blocked binding of [
18F]MSX-122F to CXCR4. This strongly
supports that MSX-122 blocks certain CXCR4 functions via
binding to the CXCL12-binding site and interfering with
CXCR4/CXCL12-mediated signaling.
Like our previous anti-CXCR4 compounds, MSX-122 can
intervene in the Gai-signaling pathway (cAMP modulation), but
not the Gq-pathway (calcium flux) [48]. This limited functionality
of MSX-122 as a CXCR4 inhibitor may represent a significant
safety asset, since the CXCL12/CXCR4-axis is critical to normal
physiology. In the normal adult, the CXCL12/CXCR4 signaling
is involved in the homing and retention of hematopoietic
progenitor cells in the bone marrow. These progenitor cells
express high levels of CXCR4, and are attracted to CXCL12
produced by stromal cells in specialized bone marrow niches. In
addition, CXCL12 acts as a major chemoattractant for stem cells
and some differentiated cells in the pathological contexts of tissue
regeneration/repair [49,50,51,52]. Therefore, our functionally
circumscribed CXCR4 inhibitor, which blocks chemotaxis and
homing of the CXCR4-positive cells to distant organ sites when
enriched with CXCL12 in the stroma without disturbing the
retention of hematopoietic progenitor cells in the bone marrow,
presages a unique therapeutic application of MSX-122 for cancer
metastasis or inflammation.
In summary, the novel small molecule, MSX-122, identified by
rational design and analysis of emerging structural and pharma-
cologic data, is a partial inhibitor of CXCR4/CXCL12 functions.
The compelling features of the MSX-122 profile include: (i) potent
inhibition of CXCR4/CXCL12 actions (IC50,10 nM); (ii) ease of
production on a large scale; (iii) effectiveness as an anti-
inflammatory and anti-metastatic agent in vivo; and (iv) unique
property of blocking homing and recruitment without mobilizing
stem cells.
Materials and Methods
Synthesis of N,N’-Di-2-pyrimidinyl-1,4-
benzenedimethanamine (MSX-122)
MSX-122 was prepared similarly to the preparation of WZ811
[23] following a one-pot reductive amination strategy (Figure 1A)
[24]. Details of MSX-122 synthesis and characterization data are
provided in Data S1.
A Binding Affinity Assay, Invasion Assay, and cAMP Assay
For binding affinity assay, MDA-MB-231 cells cultured in an 8-
well slide chamber were preincubated with MSX-122 at 1, 10,
100, and 1000 nM. Then the cells were fixed with 4%
formaldehyde and incubated with 50 nM biotinylated TN14003,
and followed by Rhodamine staining [23]. Matrigel invasion
chambers from BD Biocoat Cellware (San Jose, CA) were used for
invasion assays. MDA-MB-231 cells were cultured on a layer of
Matrigel in the upper chamber with testing compounds at 10 or
100 nM while 200 ng/mL CXCL12 was added in the lower
chamber as a chemoattractant. cAMP assay was performed using
U87CD4CXCR4 cells (AIDS Consortium) or MDA-MB-435 cells
transfected with CXCR4 plasmid (Missouri S&T cDNA resource
center). Perkin-Elmer’s LANCE cAMP assay kit (Cat # AD0262),
based on time-resolved fluorescence resonance energy transfer
(TR-FRET), was used to determine whether MSX-122 could
block cAMP modulation induced by the CXCR4/CXCL12
interaction as previously described [23].
F-18 Labeling
Fluorine-18 was prepared by the
18O (p,n)
18F reaction using
18O enriched water by PetNet Solutions at Emory University
Yerkes National Primate Center. The aqueous solution was
transferred into a vial located in a hot cell in the Yerkes
Radiochemistry Laboratory. The solution was then transferred
into a mini cell which houses a chemical process control unit
where
18F was trapped on an anion exchange resin cartridge. The
18F was then eluted with a potassium carbonate solution into a
vessel containing Kryptofix 2,2,2 and the mixture dried by
azeotropic distillation with acetonitrile. The complexed
18F was
reacted with 3 mg chloro- precursor in DMSO at 170uC. The
diluted reaction product was purified by C18 reverse phase HPLC
using a Waters Xterra Prep RP18 5 mm, 196100 mm column and
a mobile phase of 50:50:0.1 EtOH: H2O: Et3N. The desired
compound was isolated from the diluted fractions by C18 solid
phase extraction and eluted by ethanol into a vial containing
isotonic saline. The mixture was sterilized by filtration through a
0.2 micron filter. The chemical and radiochemical purity was
determined by analytical HPLC utilizing a Waters Nova-Pak C18
3.96150 mm column with a mobile phase of 70:30:0.1 MeOH:
H2O: Et3N. The specific activity was estimated based upon the
lower limit of detectable unlabeled reference compound.
Ligand Competition
The cell binding assays were performed with SCCHN
metastatic subclones 686LN-Ms cells. In this study, approximately
2610
6 cells were exposed to 5 mCi of F-18 labeled radioligand in
1% BSA in PBS (actual MSX-122F concentration was 12.5 nM)
and incubated at 37uC for 60 minutes. Each assay condition was
performed in triplicate. For competition test, the cells were
preincubated with different concentrations of CXCL12 of 11, 33,
100 and 400 nM for 15 mins, and then incubated with the
radioligands in the same condition as above. After incubation, cells
were centrifuged and rinsed with ice-cold 1% BSA in PBS to
remove unbound activity in the supernatant. The activity in the
tubes was counted in an automated c-counter (AccuFLEXc7001,
Aloka, Co. Ltd., Japan). The data from these studies were
normalized as percent uptake relative to standard per 2610
6 cells.
Real-time RT–PCR Analysis
Human CXCR4-specific primers and ß-actin primers used
were the same as those described in our previous report [20]. The
human CXCR7-specific primers for 220 bp are 59-
ACGTGGTGGTCTTCCTTGTC and 59-AAGGCCTTCAT-
CAGCTCGTA (GenBank accession number NM_020311). The
primers for TNF-a are 59-AGGCTGCCCCGACTACGT and 59-
GACTTTCTCCTGGTATGAGATAGCAAA (GenBank acces-
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TCGCTCAGGGTCACAAGAAA and 59- CATCAGAGG-
CAAGGAGGAAAAC (GenBank assession number NM_008361),
and those for IL-6 are 59-ACAAGTCGGAGGCTTAATTACA-
CAT and 59-TTGCCATTGCACAACTCTTTTC (Genbank ac-
cession number X54542).Details are provided inTableS1.
Detailed conditions and data analysis were described in our
previous study [53].
DSS-induced Colitis
Male C57BL/6 mice (age 5–6 weeks) were treated with 3%
DSS in drinking water to induce colitis. To determine the effect of
MSX-122, a group of mice were given DSS and daily i.p. injection
of MSX-122, 10 mg/kg (dissolved in 10% DMSO and 45% 2-
hydroxypropyl-b cyclodextrin (Fluka)). Half of the DSS-treated
mice were sacrificed at day 7, whereas the remaining mice were
kept for an additional 3 days. Control mice were given either daily
i.p. injection of vehicle or MSX-122 for 10 days. The colon was
removed and processed as previously reported [54]. Neutrophil
infiltration was quantified by measuring myeloperoxidase (MPO)
activity as described previously [41]. Anti-CXCR4 antibody and
anti-CD4 antibody were purchased from Abcam and BD
Pharmingen, respectively.
Bleomycin-induced Lung Fibrosis
Mice were anesthetized by isofluorane inhalation; the trachea
was exposed using sterile techniques and 4 U/kg bleomycin
(Sigma) in 100 mL PBS or PBS vehicle was injected into the
tracheal lumen. After inoculation, the incision was closed and the
animals were allowed to recover. Each group has 10 mice that
received 10 mg/kg of MSX-122ms or PBS intraperitoneally
1 day before bleomycin treatment and daily for 20 days. Lungs
harvested 20 days after bleomycin treatment were analyzed
histologically by H&E-staining and imaged under microscope
[45].
Paw Inflammation Suppression Test
Acute inflammation was induced by subcutaneous injection of
50 mLo fl-carrageenan (1% w/v in saline) into one of the hind
paws of female C57BL/6J mice (Jackson Laboratories); the other
hind paw was used as a non-inflammation control. In the
treatment group, MSX-122 was administered i.p. at 10 mg/kg,
30 min following carrageenan challenge and continued daily.
The animals were sacrificed 74 h after induction of inflammation
and 2 h after the last injection of MSX-122. The final paws were
photographed and measured for thickness from the ‘‘palm’’ to
t h eb a c ko ft h ep a wb yac a l i p e r .T h e s ew e r ec o m p a r e dt ot h e
volume of carrageenan untreated contralateral paw to obtain the
edema volume; the volume of the contralateral paw was
subtracted from the volume of the carrageenan injected paw to
obtain the edema volume. The inflammation suppression
percentage was calculated by comparing the drug treated group
to the control group. Twelve mice per group were used to
determine the effect of MSX-122 on acute inflammation as
previously described [45].
Animal Experiments for Metastasis
Six- to eight-week-old female nude mice (Taconic Farms) were
given injections of 1.5610
6 MDA-MB-231 breast cancer cells
mixed with the compound (1 mM, less than 5 min preincubation)
through the tail vein (10/group). From the following day, mice in
the treated group were given 4 mg/kg MSX-122ms daily by i.p.
injection. The animals were sacrificed 35 days after the tumor cell
injection. Whole lung tissues were harvested and sectioned for
real-time RT-PCR for human CXCR4 and H&E histostaining to
evaluate the metastatic tumor area in five fields per section
microscopically. These experiments were repeated once more to
confirm the results. For the head and neck cancer animal model,
metastatic subclones of 686LN-Ms cells were injected in the same
way as MDA-MB-231 cells as described previously [21].
[
18F]FDG-PET was performed as described previously [21]. For
the uveal melanoma micrometastasis mouse model, on day 0, each
mouse was inoculated with 1610
6 wild-type OMM2.3 cells
expressing HGF/TGF-b/CXCR4/MMP2 into the posterior
chamber of right eye. On day 3, mice were treated with 10 mg/
kg MSX-122 in 0.1 mL volume of 45% CD daily by i.p. injection,
whereas the control mice were injected with 0.1 mL 45% CD
only. On day 7, eyes with tumor were enucleated. The growth of
tumor was checked by histological methods. On day 28, hepatic
tissues were collected and fixed in 10% formalin, processed, H&E
stained, and the number of hepatic micrometastases was counted
under microscope. Six sections through the center of the liver were
microscopically examined (Olympus BX41, Tokyo, Japan) for the
presence of micrometastases (,100 mm diameter) and the average
number of micrometastases per section was determined [45]. Ten
mice per group were used. A table summarizing animal
experiments for three metastasis models can be found in the Data
S3.
All the animals were housed in the Emory animal facility. All
protocols for animal studies were reviewed and approved by the
Institutional Animal Care and Use Committee at Emory
University ( IACUC protocol numbers:170-2008, 155-2007, 029-
2008, and 065-2006). Emory DAR (Division of Animal Resources)
has experienced clinical veterinary and animal caretaker support
staff who are well trained in the care of rodents. All animals were
monitored daily by the investigators and by members of the
clinical veterinary staff concerning general health and to detect
signs of discomfort. Any animal showing signs of discomfort, pain
or distress was sacrificed immediately following IACUC guideline
for endpoints. All reasonable measures were taken to ensure the
health and well being of the animals during the course of the study.
The procedures to be used for animal care were consistent with
those established by the NIH and the vivarium was fully accredited
by the AAALAC. All experimental results adhere to the ARRIVE
guidelines for the reporting of animal research [55].
Statistical Analyses
All statistical significances were determined by Student’s t-test.
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